ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

NCT07448610 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Spinal Muscular Atrophy

Interventions

DRUG: Onasemnogene Abeparvovec-brve

Sponsor

Novartis Pharmaceuticals